These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22727113)

  • 1. Relapse of imported Plasmodium vivax malaria is related to primaquine dose: a retrospective study.
    Townell N; Looke D; McDougall D; McCarthy JS
    Malar J; 2012 Jun; 11():214. PubMed ID: 22727113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of relapsing Plasmodium vivax malaria.
    Chu CS; White NJ
    Expert Rev Anti Infect Ther; 2016 Oct; 14(10):885-900. PubMed ID: 27530139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relapse of imported vivax malaria despite standard-dose primaquine therapy: an investigation with molecular genotyping analyses.
    Chiang TY; Lin WC; Kuo MC; Ji DD; Fang CT
    Clin Microbiol Infect; 2012 Jul; 18(7):E232-4. PubMed ID: 22448875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
    Llanos-Cuentas A; Lacerda MVG; Hien TT; Vélez ID; Namaik-Larp C; Chu CS; Villegas MF; Val F; Monteiro WM; Brito MAM; Costa MRF; Chuquiyauri R; Casapía M; Nguyen CH; Aruachan S; Papwijitsil R; Nosten FH; Bancone G; Angus B; Duparc S; Craig G; Rousell VM; Jones SW; Hardaker E; Clover DD; Kendall L; Mohamed K; Koh GCKW; Wilches VM; Breton JJ; Green JA
    N Engl J Med; 2019 Jan; 380(3):229-241. PubMed ID: 30650326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of an Unsupervised Primaquine Regimen for Preventing Plasmodium vivax Malaria Relapses in Northeast Myanmar: A Single-Arm Nonrandomized Observational Study.
    Malla P; Wang Z; Brashear A; Yang Z; Lo E; Baird K; Wang C; Cui L
    J Infect Dis; 2024 May; 229(5):1557-1564. PubMed ID: 38041857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapse of Plasmodium vivax and Plasmodium ovale Malaria With and Without Primaquine Treatment in a Nonendemic Area.
    Wångdahl A; Sondén K; Wyss K; Stenström C; Björklund D; Zhang J; Hervius Askling H; Carlander C; Hellgren U; Färnert A
    Clin Infect Dis; 2022 Apr; 74(7):1199-1207. PubMed ID: 34216464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal primaquine use for radical cure of Plasmodium vivax and Plasmodium ovale malaria in Japanese travelers--A retrospective analysis.
    Shimizu S; Kikuchi T; Koga M; Kato Y; Matsuoka H; Maruyama H; Kimura M;
    Travel Med Infect Dis; 2015; 13(3):235-40. PubMed ID: 25482427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasmodium vivax malaria relapses at a travel medicine centre in Rio de Janeiro, a non-endemic area in Brazil.
    Pedro RS; Guaraldo L; Campos DP; Costa AP; Daniel-Ribeiro CT; Brasil P
    Malar J; 2012 Jul; 11():245. PubMed ID: 22839416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent Plasmodium vivax malaria due to dose-dependent primaquine resistance: a case report.
    Kristensen KL; Dragsted UB
    Scand J Infect Dis; 2014 Jan; 46(1):63-5. PubMed ID: 23957539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax.
    Milligan R; Daher A; Villanueva G; Bergman H; Graves PM
    Cochrane Database Syst Rev; 2020 Aug; 8():CD012656. PubMed ID: 32816320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resolving the cause of recurrent Plasmodium vivax malaria probabilistically.
    Taylor AR; Watson JA; Chu CS; Puaprasert K; Duanguppama J; Day NPJ; Nosten F; Neafsey DE; Buckee CO; Imwong M; White NJ
    Nat Commun; 2019 Dec; 10(1):5595. PubMed ID: 31811128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primaquine 30 mg/day versus 15 mg/day during 14 days for the prevention of Plasmodium vivax relapses in adults in French Guiana: a historical comparison.
    Valdes A; Epelboin L; Mosnier E; Walter G; Vesin G; Abboud P; Melzani A; Blanchet D; Blaise N; Nacher M; Demar M; Djossou F
    Malar J; 2018 Jun; 17(1):237. PubMed ID: 29921273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
    Lacerda MVG; Llanos-Cuentas A; Krudsood S; Lon C; Saunders DL; Mohammed R; Yilma D; Batista Pereira D; Espino FEJ; Mia RZ; Chuquiyauri R; Val F; Casapía M; Monteiro WM; Brito MAM; Costa MRF; Buathong N; Noedl H; Diro E; Getie S; Wubie KM; Abdissa A; Zeynudin A; Abebe C; Tada MS; Brand F; Beck HP; Angus B; Duparc S; Kleim JP; Kellam LM; Rousell VM; Jones SW; Hardaker E; Mohamed K; Clover DD; Fletcher K; Breton JJ; Ugwuegbulam CO; Green JA; Koh GCKW
    N Engl J Med; 2019 Jan; 380(3):215-228. PubMed ID: 30650322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
    Llanos-Cuentas A; Lacerda MV; Rueangweerayut R; Krudsood S; Gupta SK; Kochar SK; Arthur P; Chuenchom N; Möhrle JJ; Duparc S; Ugwuegbulam C; Kleim JP; Carter N; Green JA; Kellam L
    Lancet; 2014 Mar; 383(9922):1049-58. PubMed ID: 24360369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border.
    Takeuchi R; Lawpoolsri S; Imwong M; Kobayashi J; Kaewkungwal J; Pukrittayakamee S; Puangsa-art S; Thanyavanich N; Maneeboonyang W; Day NP; Singhasivanon P
    Malar J; 2010 Nov; 9():308. PubMed ID: 21040545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico.
    Gonzalez-Ceron L; Rodriguez MH; Sandoval MA; Santillan F; Galindo-Virgen S; Betanzos AF; Rosales AF; Palomeque OL
    Malar J; 2015 Oct; 14():426. PubMed ID: 26518132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher-Dose Primaquine to Prevent Relapse of
    Chamma-Siqueira NN; Negreiros SC; Ballard SB; Farias S; Silva SP; Chenet SM; Santos EJM; Pereira de Sena LW; Póvoa da Costa F; Cardoso-Mello AGN; Marchesini PB; Peterka CRL; Viana GMR; Macedo de Oliveira A
    N Engl J Med; 2022 Mar; 386(13):1244-1253. PubMed ID: 35353962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria.
    Baird JK; Louisa M; Noviyanti R; Ekawati L; Elyazar I; Subekti D; Chand K; Gayatri A; Instiaty ; Soebianto S; Crenna-Darusallam C; Djoko D; Hasto BD; Meriyenes D; Wesche D; Nelwan EJ; Sutanto I; Sudoyo H; Setiabudy R
    JAMA Netw Open; 2018 Aug; 1(4):e181449. PubMed ID: 30646129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
    Douglas NM; Poespoprodjo JR; Patriani D; Malloy MJ; Kenangalem E; Sugiarto P; Simpson JA; Soenarto Y; Anstey NM; Price RN
    PLoS Med; 2017 Aug; 14(8):e1002379. PubMed ID: 28850568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short report: a consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria.
    Schwartz E; Regev-Yochay G; Kurnik D
    Am J Trop Med Hyg; 2000 Mar; 62(3):393-5. PubMed ID: 11037784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.